Dainippon Licenses Out an Antipsychotic Agent
Dainippon Pharmaceutical Co., Ltd. (gDainipponh, President: Kenjiro Miyatake) announced today that Dainippon had concluded an Agreement to license out Dainipponfs original antipsychotic agent gBlonanserinh (AD-5423), which is under development in Japan, to the Spanish pharmaceutical company Almirall Prodesfarma, S.A. (gAlmirallh).
Under this License Agreement, Almirall has received the exclusive development and marketing rights of Blonanserin for the world, except Japan, China, Taiwan and South Korea.
Blonanserin is an antipsychotic agent with novel chemical structure, which is different from the existing antipsychotic agents already launched in the market. Blonanserin has Dopamin 2 and 5-HT2 receptor antagonistic properties, and is expected to demonstrate efficacy on negative symptoms, such as blunted affect, disturbance of volition as well as positive symptoms, such as phantasm and delusion. Also, clinical results suggest its fewer adverse drug reactions, such as extrapyramidal symptoms and hypotension, in comparison with other agents with a similar mechanism of action.
Presently, clinical trials of Blonanserin are on going at the Phase III stage of development in Japan.
Almirall is the largest Spanish-owned pharmaceutical company. Dainippon received the development and marketing rights of Almirallfs original antiallergic agent gEbastelh from Almirall under an agreement of licensing for Japan and Taiwan. Ebastel is currently one of Dainipponfs major products in the Japanese market.
Information on Almirall:
*Company name: Almirall Prodesfarma, S.A.
*Head office: General Mitre, 151, 08022 Barcelona, Spain
*President: Dr Jorge Gallardo
*Annual Sales (1999): ESP. 91,400 million (approximately 60 billion Japanese Yen)
*Numbers of employees: 1,800